Company Overview
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | -1.74% |
| 6 Months: | +7.25% |
| 3 Months: | -1.74% |
| 1 Month: | +16.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)55.52 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BNTC Benitec Biopharma Inc. R2K | 13.02 | -14.00 | $447.29M | 0.00% | -42.71% | -29.58% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Dec 2019 | Mar 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.00K | 77.00K | 28.00K | 55.00K | 1.00K | 1.00K | 0 | 25.00K | 48.00K | 0 | 14.00K | 54.00K | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 |
| Operating Income | -1.17M | -2.11M | -2.11M | -2.69M | -3.26M | -3.79M | -4.82M | -4.83M | -3.46M | -4.58M | -5.61M | -4.34M | -5.87M | -6.93M | -4.14M | -5.79M | -10.80M | -15.34M | -9.83M | -9.80M | -13.38M | -13.58M |
| Net Income | -1.15M | -2.09M | -2.10M | -2.72M | -3.25M | -3.91M | -5.04M | -4.82M | -3.27M | -5.09M | -5.41M | -4.40M | -5.95M | -6.80M | -4.28M | -5.06M | -9.55M | -14.50M | -8.80M | -8.96M | -11.84M | -11.94M |
| Diluted EPS | - | - | - | - | - | - | -0.62 | -0.59 | -0.40 | -7.98 | -3.34 | -2.67 | -3.05 | -2.64 | -0.23 | -0.18 | -0.26 | -0.38 | -0.21 | -0.22 | -0.26 | -0.24 |
| R&D Expense | 423.00K | 599.00K | 805.00K | 774.00K | 1.17M | 2.76M | 2.78M | 3.15M | 2.17M | 2.66M | 3.76M | 3.17M | 4.43M | 5.10M | 2.57M | 3.58M | 5.38M | 6.50M | 2.87M | 3.37M | 5.83M | 6.30M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 12.20M | 102.00K | 59.00K | 73.00K | 75.00K | 0 | - |
| Operating Income | 2.58M | -8.28M | -13.60M | -17.85M | -19.08M | -22.49M | -41.77M |
| Net Income | 2.61M | -8.27M | -13.88M | -18.21M | -19.56M | -21.75M | -37.92M |
| Diluted EPS | - | - | -3.23 | -37.88 | -14.12 | -1.22 | -1.05 |
| R&D Expense | 4.57M | 3.00M | 7.02M | 11.27M | 12.77M | 15.61M | 18.33M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 19.23M | 11.59M | 21.38M | 5.97M | 4.46M | 52.21M | 99.59M |
| Total Equity | 13.84M | 16.59M | 10.24M | 20.01M | 2.88M | 202.00K | 47.25M | 97.30M |
| Cash & Equivalents | 11.88M | 15.72M | 9.80M | 19.77M | 4.06M | 2.48M | 50.87M | 97.74M |
| Total Liabilities | - | 2.64M | 1.35M | 1.37M | 3.09M | 4.26M | 4.96M | 2.30M |
| Current Liabilities | - | 2.64M | 1.14M | 1.37M | 2.53M | 3.98M | 4.92M | 1.80M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 4.79M | -7.54M | -12.83M | -15.90M | -18.01M | -19.40M | -23.59M |
| Investing Cash Flow | -400.00K | -94.00K | -221.00K | -13.00K | -1.00K | -179.00K | -18.00K |
| Financing Cash Flow | - | 1.77M | 22.52M | - | 16.02M | 68.03M | 70.48M |
| Capital Expenditure | -404.00K | -95.00K | -221.00K | -13.00K | -1.00K | -179.00K | -18.00K |
| Free Cash Flow | 4.39M | -7.63M | -13.05M | -15.91M | -18.01M | -19.58M | -23.61M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | 21.2% | -8,118.6% | -23,044.1% | -24,457.5% | -25,441.3% | - | - |
| Net Margin % | 21.4% | -8,111.8% | -23,528.8% | -24,942.5% | -26,082.7% | - | - |
| ROE % | 15.7% | -80.8% | -69.4% | -631.8% | -9,684.2% | -46.0% | -39.0% |
| ROCE % | 15.6% | -79.2% | -67.9% | -518.9% | -3,926.1% | -47.6% | -42.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 33.62% | 11.55M | $149.90M |
| 2 | Janus Henderson Group PLC | 8.37% | 2.88M | $37.34M |
| 3 | Franklin Resources, Inc. | 6.92% | 2.38M | $30.87M |
| 4 | Adage Capital Partners GP L.L.C. | 6.17% | 2.12M | $27.53M |
| 5 | RA Capital Management, L.P. | 5.39% | 1.85M | $24.01M |
| 6 | Nantahala Capital Management, LLC | 4.19% | 1.44M | $18.67M |
| 7 | Blackrock Inc. | 3.45% | 1.19M | $15.39M |
| 8 | Vanguard Capital Management LLC | 2.71% | 931.56K | $12.09M |
| 9 | Infinitum Asset Management, LLC | 2.69% | 923.01K | $11.98M |
| 10 | Alyeska Investment Group, L.p. | 2.18% | 750.00K | $9.73M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BNTC
BNTC Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFAzTUF6c2pHQjhyTDMwOEdzRGp3WlJ6N21CNnYzM3RpY2lvYzFyR0tFUUtmQklfWDRKamVGNTJpVHN2eUR1VVN2TkVKTTNPbFJqUmxveHAwbG9xY2l4S3JBeTBTc3FHX3U4YmlsQUFRTmphTEJEQWpkRVZB?oc=5" target="_blank">BNT…
(BNTC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPSXVJYzRhWTFPOEpYaFRFMFBPZDNzeklaQUE0d0RoRVNEVkVjdDhBZS1iX1VsOVZqbVVfeFV6ZWo5eWMyMkp3OTZmX1MtYlVkMFZNekY3Tlk3aEZoeFYweFFSYkxSbk5KOTJOU1pIZmNDNkowY3RKcGNtNGNaUnV0UnBCUWJpc3ljaUMzVU…
Benitec Biopharma (NASDAQ: BNTC) director gifts 51,813 shares to donor-advised fund - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQWVFrR0RsbWYxb3E3cnIzY1pFV2pRb2o0WUNLcGFqOHI3VDNIWkp4Qm52SmZrUmxUV2xhX1FfNGpOR21RdUI0WUlzajVtb2hmNDFXeVJvLTNNQ3NzRHBoUy1DMmVZWS1oaUNINm5zeG1JR214Zk0xOHdBd3JOeEtUZFR6UjFMbUxybVhZan…
Benitec Biopharma Stock (BNTC) Opinions on $100M Stock Offering - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQcWpyYnR1WGhBWThhRzJrSlB1dmJZanhZenY1VWFJT2poREZuUVVxTEpQLVpmNWhHRTJDQ3pSS3JtYnhuS3RoYjFmbGpCWUZPOHhvSU5zZVcyS3Izb1NnbTFuajlteWM4b19SMEwwTzNGX2VUbUluZGcwckZLSGRTRHRXY3o2Qk9XbnplaG…
Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE1DRkY3S3l4NTZtdi1EcjZMWUpsNThMNEtqSVU3cnZrQ3AyY3pHa2VJLVBMRDVqeWg1MXozbWhLZE01Tjl0bjJlV2JkNmVTWkNXV25HWFhmaEtLRzBzNWZVdW9obXhPYXdPZlJiamF3aGlacGNqR0FGWTFoRGtZcDA?oc=5" target="_bla…
Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxOVndLREJMaWJqdHhHc3MxMThUbFQ4ZW9fSGI3ZzFlRHBKdnZhOTdTY2lsb2o5V3k1YmhURG9vQlVxcmhXdE5TVzNVVFlGa21RX2FqVG8tMWxBRWhGc0NnLXRfWEF2Znd0eXJWaEFVT3lsRTl6X2pKOXJ5OE1iVXhlLXZFT2ptVmJuRXpmcU…
BNTC — Frequently Asked Questions
What is the current share price of Benitec Biopharma Inc. (BNTC)?
As of 2026-07-15 16:51 PDT, Benitec Biopharma Inc. (BNTC) trades at $13.02 on NasdaqCM. Its 52-week range is $10.06 to $16.52.
What is the market capitalisation of BNTC?
Benitec Biopharma Inc. (BNTC) has a market capitalisation of $447.29M on NasdaqCM.
What is the P/E ratio of BNTC?
BNTC trades at a trailing price-to-earnings (P/E) ratio of -14.00. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 2.43.
What is the return on equity (ROE) of BNTC?
BNTC has a return on equity (ROE) of -29.58%. Its return on capital employed (ROCE) is -42.71%.
Is BNTC a good stock to buy?
This page provides a data-driven analysis of Benitec Biopharma Inc. (BNTC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.